Isoquercetin
Isoquercetin is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
60.0%
3 of 5 finished
40.0%
2 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Isoquercetin in People With Ovarian Cancer
Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
Clinical Trials (9)
A Study of Isoquercetin in People With Ovarian Cancer
Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19
Isoquercetin in Sickle Cell Anemia
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
Impact of isoQUercetin and Aspirin on Platelet Function
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9